Abstract
AbstractThe biological complexity of cancer represents a tremendous clinical challenge, resulting in the frequent failure of current treatment protocols. In the rapidly evolving scenario of a growing tumor, anticancer treatments impose a drastic perturbation not only to cancer cells but also to the tumor microenvironment, killing a portion of the cells and inducing a massive stress response in the survivors. Consequently, treatments can act as a double-edged sword by inducing a temporary response while laying the ground for therapy resistance and subsequent disease progression. Cancer cell dormancy (or quiescence) is a central theme in tumor evolution, being tightly linked to the tumor’s ability to survive cytotoxic challenges, metastasize, and resist immune-mediated attack. Accordingly, quiescent cancer cells (QCCs) have been detected in virtually all the stages of tumor development. In recent years, an increasing number of studies have focused on the characterization of quiescent/therapy resistant cancer cells, unveiling QCCs core transcriptional programs, metabolic plasticity, and mechanisms of immune escape. At the same time, our partial understanding of tumor quiescence reflects the difficulty to identify stable QCCs biomarkers/therapeutic targets and to control cancer dormancy in clinical settings. This review focuses on recent discoveries in the interrelated fields of dormancy, stemness, and therapy resistance, discussing experimental evidences in the frame of a nonlinear dynamics approach, and exploring the possibility that tumor quiescence may represent not only a peril but also a potential therapeutic resource.
Funder
Associazione Italiana per la Ricerca sul Cancro
Publisher
Springer Science and Business Media LLC
Reference186 articles.
1. Marjanovic, N. D., Hofree, M., Chan, J. E., Canner, D., Wu, K., Trakala, M., et al. (2020). Emergence of a high-plasticity cell state during lung cancer evolution. Cancer Cell, 38(2), 229–246 e213. https://doi.org/10.1016/j.ccell.2020.06.012
2. Huang, S. (2021). The logic of cancer treatment: why it is so hard to cure cancer. In B. Strauss et al. (Eds.), Rethinking cancer: A new paradigm for the post-genomics era (pp. 63–128). MIT Press Book.
3. De Angelis, M. L., Francescangeli, F., La Torre, F., & Zeuner, A. (2019). Stem cell plasticity and dormancy in the development of cancer therapy resistance. Frontiers in Oncology, 9, 626. https://doi.org/10.3389/fonc.2019.00626
4. Huang, S. (2021). Reconciling non-genetic plasticity with somatic evolution in cancer. Trends Cancer, 7(4), 309–322. https://doi.org/10.1016/j.trecan.2020.12.007
5. Huang, S., & Kauffman, S. (2013). How to escape the cancer attractor: Rationale and limitations of multi-target drugs. Seminars in Cancer Biology, 23(4), 270–278. https://doi.org/10.1016/j.semcancer.2013.06.003
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献